IRMD
Research Snapshot
Static fundamentals, valuation context, and investor signals for IRADIMED CORPORATION (IRMD).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
23.8%
ROIC, 20.5% FCF margin
Growth
21.5%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 8.0x current ratio
Superinvestors
1
Top: Polen Capital Management (0.0%)
Strengths to research
- Revenue compounded at 21.5% over five years.
- Free cash flow compounded at 26.2% over five years.
- Return on equity is strong at 23.8%.
- Free cash flow margin is healthy at 20.5%.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for IRMD.
Grade C
56
/ 100
Financial Charts
No financial data available for IRMD (annual).
1 superinvestors own IRMD
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 20,744 | $2M | 0.01% | 0.0% |